SCHEMBL94478

SCHEMBL94478

[C]1=NSSC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5101921 0.50
SCHEMBL1450836 0.48
SCHEMBL5464130 0.48
SCHEMBL3066105 0.42
SCHEMBL561897 0.34
SCHEMBL138192 0.34
Ammonia Solution, Strong SCHEMBL30436342 0.29
SCHEMBL31091685 0.29
SCHEMBL4895995 0.25
SCHEMBL7579781 0.25

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2083 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2023-10-05 US claimed
EP-4251618-A1 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Sage Therapeutics, Inc. (US) 2023-10-04 EP claimed
CN-116235315-A Additive, lithium secondary battery electrolyte comprising same, and lithium secondary battery 三星SDI株式会社 2023-06-06 CN claimed
WO-2022115620-A1 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SAGE THERAPEUTICS, INC. (US) 2022-06-02 WO claimed
WO-2022115521-A1 (HETEO)ARYL SUBSTITUTED PYRROLO-, PYRAZOLO- AND TRIAZOLOPYRIDAZINE DERIVATES AS MAT2A INHIBITORS SERVIER PHARMACEUTICALS, LLC (US) 2022-06-02 WO claimed
WO-2020243027-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. (US) 2020-12-03 WO claimed
CN-110938845-A Plating solution for electrolytic tinning 上村工业株式会社 2020-03-31 CN claimed
US-20150119319-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2015-04-30 US claimed
EP-1827423-B1 NOVEL CYCLIC UREAS USED AS INHIBITORS OF METALLOPROTEASES SANOFI AVENTIS DEUTSCHLAND (DE) 2010-06-30 EP claimed
US-20090269313-A1 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2009-10-29 US claimed
WO-2004055003-A1 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-01 WO claimed
US-20030203888-A1 Chromophores WELLCOME TRUST LIMITED, THE (GB) 2003-10-30 US claimed
EP-1294726-A2 IMPROVEMENTS IN AND RELATING TO CHROMOPHORES Catalyst Biomedica Ltd (GB) 2003-03-26 EP claimed
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US claimed
WO-2002000662-A1 IMPROVEMENTS IN AND RELATING TO CHROMOPHORES CATALYST BIOMEDICA LIMITED (GB) 2002-01-03 WO claimed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP claimed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO claimed
US-5532332-A METHINE LINKAGES WEAVER MAX A (US) 1996-07-02 US claimed
US-5376650-A Colorants for thermoplastic resins EASTMAN CHEMICAL COMPANY (US) 1994-12-27 US claimed
US-5254625-A Blends of a thermoplastic resin and a polymeric methine dye; molding materials; heat resistance; low volatility; nonextractable; brightness; nontoxic EASTMAN KODAK COMPANY (US) 1993-10-19 US claimed